Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lanabecestat on Rosuvastatin PK in Healthy Subjects
NCT03019549Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanabecestat in Alzheimer's disease (AD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Area Under The Drug Concentration Time Curve From Zero to Infinity at 120 hours. Started Jan 2017; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03019549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019549.